Clinical Care Options Oncology - Leukemia http://clinicaloptions.com/Oncology.aspx New treatment data and educational activities for Oncology and Hematology Clinicians en-us Clinical Care Options Oncology - Leukemia http://images.imedoptions.com/img.asp?img=cco/CCO_ONC_RSS.gif http://clinicaloptions.com/oncology Frontline Subcutaneous Low-Dose Alemtuzumab Safe and Effective in Elderly CLL Patients With 17p Deletionhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202008/Tracks/Hematology/Capsules/7048.aspxSubcutaneous low-dose alemtuzumab is as effective as frontline IV administration in elderly CLL patients with the 17p chromosomal deletion Addition of Imatinib to Hyper-CVAD May Improve Outcomes in Patients With Ph-Positive Acute Lymphoblastic Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202008/Tracks/Hematology/Capsules/7019.aspxImatinib added to hyper-CVAD resulted in a high rate of durable remissions in patients with de novo or minimally treated Ph-positive ALL Novel JAK Inhibitor INCB018424 Active in Patients With Primary Myelofibrosis and Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosishttp://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202008/Tracks/Hematology/Capsules/7004.aspxNovel oral JAK inhibitor INCB018424 associated with substantial durable reductions in spleen size in patients with primary myelofibrosis and post-polycythemia vera/essential thrombocythemia myelofibrosis New TKI Bosutinib Active in Chronic-Phase CML Resistant to Other TKIshttp://clinicaloptions.com/Oncology/Conference%20Coverage/Clin%20Onc%20June%202008/Tracks/Hematology/Capsules/7001.aspxNovel TKI bosutinib active in patients with chronic-phase CML with imatinib intolerance or resistance, or resistance to second-generation TKIs Virtual Presentation: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/CML%20VP.aspxNeil Shah, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with chronic myeloid leukemia. Virtual Presentation: Non-Hodgkin’s Lymphomahttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/Non-Hodgkin%e2%80%99s%20Lymphoma%20VP.aspxSandra J. Horning, MD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with non-Hodgkin’s lymphoma. Virtual Presentation: Chronic Lymphocytic Leukemiahttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/CLL%20VP.aspxMichael J. Keating, MB BS, discusses results presented at the 2007 hematology meeting regarding chronic lymphocytic leukemia. Virtual Presentation: Myelodysplastic Syndromehttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/MDS%20VP.aspxAllen S. Yang, MD, PhD, discusses results presented at the 2007 hematology meeting regarding current and novel therapeutic approaches for treating patients with myelodysplastic syndrome. Virtual Presentation: Acute Leukemiashttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/Acute%20Leukemias%20VP.aspxFarhad Ravandi, MD, discusses results presented at the 2007 hematology meeting regarding acute leukemias. Virtual Presentation: Multiple Myelomahttp://clinicaloptions.com/Oncology/Treatment%20Updates/Heme%20Highlights%202008/Virtual%20Presentations/Multiple%20Myeloma%20VP.aspxAmitabha Mazumder, MD, discusses new data in multiple myeloma presented at the 2007 hematology meeting. Management of a 69-Year-Old Patient With Deletion 5q Myelodysplastic Syndromehttp://clinicaloptions.com/Oncology/Treatment%20Updates/MDS%20Treatment/Interactive%20Case%20Challenges/Case%202.aspxAlan F. List, MD, reviews treatment options for a patient with del(5q) MDS. Clinical Management of a 69-Year-Old Man With Intermediate-1-Risk Myelodysplastic Syndromehttp://clinicaloptions.com/Oncology/Treatment%20Updates/MDS%20Treatment/Interactive%20Case%20Challenges/Case%201.aspxIn this Interactive Case Challenge, Azra Raza, MD, and Naomi Galili, PhD, discuss treatment options for a patient with intermediate-risk myelodysplastic syndrome and monosomy of chromosome 7. Slideset Module: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007.aspxDownload a slideset created by Charles L. Sawyers, MD, and Moshe Talpaz, MD, that reviews the latest data on chronic myeloid leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia, and the clinical implications. Expert Analysis: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Expert%20Analysis.aspxMoshe Talpaz, MD; Brian Druker, MD; Charles L. Sawyers, MD; and Allen Yang, MD, PhD, review clinical data on chronic myeloid leukemia presented at the 2007 hematology meeting. Expert Recap: Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Virtual%20Presentation%20Programs/CML/CML%20ER.aspxWatch and listen as Moshe Talpaz, MD, reviews the latest data on chronic myeloid leukemia treatment presented at the 2007 Annual Meeting of the American Society of Hematology in Atlanta, Georgia. Expert Recap: Chronic Lymphocytic Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Virtual%20Presentation%20Programs/CLL/CLL.aspxIn this Expert Recap, Michael J. Keating, MB BS, reviews the most up-to-date data on chronic lymphocytic leukemia presented at the 2007 annual hematology meeting in Atlanta, Georgia. Expert Analysis: Chronic Lymphocytic Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CLL/Expert%20Analysis.aspxJohn C. Byrd, MD, Michael J. Keating, MB BS, and Kanti Rai, MD, discuss the latest clinical data on treatment of chronic lymphocytic leukemia presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Roy A. Beveridge, MD. Expert Analysis: Acute Leukemiashttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/ALL%20AML%20APL/Expert%20Analysis.aspxHagop M. Kantarjian, MD; Dan Douer, MD; and Stephen J. Forman, MD, discuss the latest clinical data on treatment of acute leukemias presented at the 2007 Annual Meeting of the American Society of Hematology in an expert panel moderated by Mark Kirschbaum, MD. Expert Analysis: Myelodysplastic Syndromeshttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/MDS/Expert%20Analysis.aspxRead a discussion among Alan F. List, MD; Lewis R. Silverman, MD; and Azra Raza, MD, and moderated by Allan S. Yang, MD, PhD, on the key studies presented at ASH 2007 regarding treatment and pathogenesis of myelodysplastic syndromes. Pretransplant Imatinib During First Chronic Phase Associated With Improved Survival in CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/738.aspxPatients with CML in first chronic phase treated with imatinib prior to HSCT have improved survival vs patients who do not receive imatinib Nilotinib Active and Safe in Patients With Imatinib-Resistant/Intolerant Chronic-Phase Chronic Myeloid Leukemiahttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/735.aspx18-month survival rate of 91% among patients with imatinib-resistant/intolerant chronic-phase chronic myeloid leukemia treated with nilotinib Bosutinib Active and Well Tolerated in Heavily Pretreated Patients With Chronic-Phase CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/733.aspxNovel dual TKI of ABL and Src, bosutinib, induces responses in patients with treatment-experienced chronic-phase CML after previous TKI treatment failure INNO-406 Active and Well Tolerated in Patients With Ph-Positive CML and ALL Who Have Failed Multiple Tyrosine Kinase Inhibitorshttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/469.aspxINNO-406, novel dual Bcr-Abl/Lyn kinase inhibitor, demonstrates activity in imatinib-resistant/intolerant CML and ALL population Low Sensitivity BCR-ABL Mutants Identified in Vitro Correspond With Reduced Response to Dasatinib in Patients With Chronic-Phase CMLhttp://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/319.aspxSensitivity of BCR-ABL mutants to dasatinib corresponds to hematologic and cytogenetic response rates in patients with chronic-phase CML. Dasatinib Induces High Response Rates and Is Well Tolerated in Treatment-Naive Patients With Early CP CML http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/30.aspx In this study, most patients with treatment-naive, early chronic-phase chronic myeloid leukemia achieved complete cytogenetic response after 18 months of dasatinib therapy Response to Imatinib Sustained in 6-Year Follow-up With Continued Safety in Newly Diagnosed Chronic-Phase CML http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/25.aspx Results of 6-year follow-up study demonstrate continued safety and efficacy of imatinib therapy in chronic-phase CML. Time to Complete Cytogenetic Response Does Not Predict Outcomes in Chronic-Phase CML Treated With Imatinib http://clinicaloptions.com/Oncology/Conference%20Coverage/Hematology%202007/Tracks/CML/Capsules/27.aspx Complete cytogenetic response to imatinib in patients with newly diagnosed chronic-phase CML was associated with excellent outcomes, regardless of when the response was achieved.